INTRODUCTION

BDG LifeSciences' Research Project Training Program is a one-of-a-kind initiative designed to strengthen your profile and enhance career opportunities, whether for jobs or higher studies, by offering the chance to work on novel research projects using the latest technologies in bioinformatics. Since 2010, this program has addressed the critical need for high-quality publications by combining innovative teaching methods with practical applications. Conducted entirely online, it provides participants with the flexibility to choose session timings while saving on travel, accommodation, and food expenses. With over 88 research projects successfully completed and published at the international level, this program is ideal as a major or thesis project for final-year students or for those looking to advance their profiles.

Applications are now open for 5 SEATS in our 93 novel research project entitled "Integrative Single-Cell Transcriptomics and CRISPR-Cas9 Perturbation Modeling for Regulatory Network Mapping in the Tumour Microenvironment". 

---

Introduction of the Project

The CRISPR-Driven Single-Cell Research Project by BDG LifeSciences is an advanced, structured, research-intensive initiative designed to decode the complexities of the tumour microenvironment using CRISPR-Cas9 perturbation analysis and single-cell transcriptomics.

Modern cancer biology demands more than theoretical knowledge. It requires systems-level thinking, computational depth, and the ability to interpret gene regulatory rewiring at cellular resolution. This project integrates CRISPR gene editing, bioinformatics, genomics, and immunogenomics into a unified research workflow aligned with global scientific standards.

This is not a short-term workshop. It is a long-term, publication-oriented research experience built for serious learners who aspire to build a strong foundation in computational cancer genomics.

---

Objective of the Project

The primary objective of this research project is:

• To model and analyze CRISPR-Cas9 perturbations at single-cell resolution

• To decode gene regulatory network (GRN) rewiring within the tumour microenvironment

• To connect genomic perturbations with cancer immunotherapy insights

• To develop publication-ready analytical frameworks

• To train participants in hypothesis-driven computational research

The focus is on scientific thinking, analytical rigor, and translational relevance.

---

Methodology

The project follows a structured, multi-phase research framework:

Phase 1: Data Acquisition & Preprocessing

• Collection and curation of single-cell RNA-seq datasets

• Quality control and normalization

• Dimensionality reduction and clustering

Phase 2: CRISPR Perturbation Modeling

• Analysis of CRISPR-Cas9 editing outcomes

• Differential gene expression analysis

• Integration of perturbation data with cellular heterogeneity

Phase 3: Gene Regulatory Network Inference

• GRN construction and regulatory rewiring analysis

• Pathway enrichment and functional annotation

• Biological interpretation aligned with immunotherapy relevance

Phase 4: Scientific Reporting & Publication Framework

• Visualization of findings

• Structured research documentation

• Manuscript-oriented workflow training

Participants will use globally accepted open-source tools widely cited in high-impact journals. All sessions combine theory + hands-on practice using various computational tools.

---

Probable Outcome

By the end of this project, participants will:

• Develop a strong conceptual understanding of single-cell transcriptomics integrated with CRISPR perturbation analysis.
• Gain hands-on expertise in scRNA-seq preprocessing, clustering, and cell-type annotation.
• Acquire practical skills in CRISPR perturbation modeling and gene regulatory network inference.
• Identify key regulatory drivers and immune modulators within tumour microenvironments.
• Produce a comprehensive computational study suitable for journal publication, conference presentation, or doctoral-level research.
• The broader impact of this project lies in its potential to advance precision immuno-oncology research by enabling mechanistic insights into tumour–immune regulatory circuits using purely computational approaches.
• Video Recordings of each session.
• Certificate.
• Recommendation Letter for Employment or Higher Studies.
• References for Jobs or PhD positions.
• LinkedIn Profile Title as Research Associate at BDG Lifesciences for experience.

---

Why You Should Attend

Because the future of biomedical research belongs to those who can:

• Interpret single-cell omics data

• Understand CRISPR-based functional genomics

• Build regulatory network models

• Translate computational findings into biological insights

This project develops analytical maturity — not just technical familiarity.

It prepares you to think like a research scientist.

---

What Are the Benefits of This Program?

• Hands-on experience with CRISPR perturbation datasets

• Deep understanding of single-cell RNA sequencing analysis

• Exposure to tumour microenvironment modeling

• Training in gene regulatory network inference

• Research workflow aligned with international publication standards

• Structured long-term scientific mentorship

• Enhanced research portfolio

---

How It Will Help You in Your Career

This project can significantly strengthen your academic and professional trajectory:

• Improves PhD and research fellowship applications

• Builds a competitive profile for genomics and bioinformatics roles

• Opens opportunities in cancer research labs

• Enhances readiness for computational biology positions

• Supports transition into immunogenomics and translational research

• Develops publication-oriented scientific thinking

Participants gain skills that are directly relevant to emerging domains such as:

CRISPR therapeutics, precision oncology, RNA-based interventions, and systems immunology.

---

Why Choose BDG LifeSciences for this Program?

BDG LifeSciences has successfully delivered 92+ research-oriented programs across genomics, bioinformatics, NGS, molecular modeling, and AI-driven life sciences domains.

Our strengths include:

• Structured, research-centric frameworks

• Real dataset-based training

• Focus on analytical depth

• Publication-oriented guidance

• Global participant base

• Strong reputation in computational life sciences training

This is our 93rd research initiative, reflecting sustained commitment to advancing scientific education.

---

Target Audience

This research project is designed for:

• Life Sciences students (UG, PG, PhD)

• Biotechnology and Bioinformatics professionals

• Researchers interested in CRISPR and genomics

• Computational biology aspirants

• Individuals preparing for PhD admissions

• Professionals transitioning into cancer genomics research

---

Comparable Global Programs

North America (USA): Top institutions offer multi-week genomics/CRISPR certificate courses with live instruction and certification. For example, Harvard’s 9-week online course “CRISPR: Gene-Editing Applications” (instructor-led via GetSmarter) costs $1,680[1]. Harvard Medical School’s 10-week HMX “Genetics” course (online with live support) is $1,025[2]. These high-reputation programs provide certificates (Harvard VPAL certificate or HMX certificate) and include interactive components, although they do not offer 1-on-1 mentorship. (Stanford Online’s genomics certificates have courses at ~$695 each[3], so a multi-course certificate runs a few thousand dollars, although we could not directly cite Stanford’s pricing in detail.)

Europe: Professional certificates can be more expensive. For example, the Royal College of Physicians of Ireland (RCSI) offers an 11‑month online Certificate in Cancer Genetics & Genomics (mix of asynchronous modules and weekly live tutorials) priced at €3,600 (~$3,900)[4]. This program includes regular live virtual tutorials and a final assessment (providing a QQI-accredited certificate), and is taught by experts in the field. Similarly, an 11-month UK Postgraduate Certificate in Genomic Medicine (Cambridge) or European courses would be in the €3k–€4k range. These illustrate that thorough genomics programs with weekly live sessions can cost several thousand USD in Europe.

Asia: Dedicated bioinformatics/genomics training with mentorship also ranges in the low- to mid-thousands USD. For instance, an industry‑aligned Bioinformatics Professional Program in India (featuring faculty mentors) charged ₹125,000 total (about $1,500 USD) for a 12-month curriculum[5]. Although shorter (4–6 month) programs are less common in published data, similar Asia-based offerings (often by edtech or biotech institutes) typically price multi-month certificates on the order of ₹50k–₹150k (roughly $600–$1,800). In Singapore, Duke-NUS’s executive genomics certificate charged S$1,350 (~$1,000) per course[6] (4 courses total ≈ $4,000), indicating similarly high costs. In summary, Asian certificate programs with mentorship are roughly $1,000–$2,000 for shorter (<6 month) courses, scaling upward if extended.

Pricing Summary and Competitive Estimate

In sum, live/mentored genomics courses from leading providers typically cost on the order of a few thousand dollars. Harvard’s short CRISPR/genetics programs run $1–1.7K for ~2–2.5 months[1][2]. European 10–12 month certificates approach $4K[4]. Asian offerings (even though data is sparse) suggest ~$1–2K for intensive programs[5]. Given BDG Lifesciences’ program is 4–6 months long with live instruction and personalized (1-on-1 or small-group) mentorship plus a certificate, a competitive fee would likely be in the $2,000–$4,000 USD range. This estimate aligns with the per-month costs implied by those comparables (roughly $300–$800 per month) while recognizing BDG’s additional mentorship component.

Sources: Price and format data from published program descriptions[1][2][4][5].

[1] Harvard VPAL CRISPR: Gene-editing Applications | Harvard University

https://pll.harvard.edu/course/harvard-vpal-crispr-gene-editing-applications

[2] HMX Genetics | Harvard University

https://pll.harvard.edu/course/hmx-genetics

[3] Tuition & Fees - Stanford Online

https://online.stanford.edu/graduate-courses-certificates/tuition-fees

[4] Certificate in Cancer Genetics and Genomics (Postgraduate)

https://courses.rcpi.ie/product?catalog=Certificate-in-Cancer-Genetics-and-Genomics

[5] SHRM x Industry PGP Bioinformatics

https://shrmbio.com/wp-content/uploads/2024/06/SHRM-x-industry-PGP-bioinformaticspdf-compressed.pdf

[6]  Executive Certificate in Clinical Genomics

https://www.duke-nus.edu.sg/cll/allcourses/executive-certificate-in-clinical-genomics

---

T & C

• Post-Registration Details: Upon successful registration and payment, you will receive a welcome email containing:
• Instructions for system preparation and software installation.
• Relevant files, research papers, and materials.
• Session Videos: After each training session, a recording of the same session will be provided for your reference.
• Gmail/YouTube ID Requirement: Registration must be done using a Gmail ID or the email ID linked to your YouTube account. All videos will be uploaded privately on YouTube and can only be accessed by participants of the project.
• Non-Refundable and Non-Transferable: Registration fees are strictly non-refundable and non-transferable under any circumstances.
• Training Session Commitment: Once your system is prepared, inform us of your preferred training schedule. If you are unable to attend a scheduled session, the steps for that phase will be sent to you via email.
• Certificate Eligibility: A certificate will only be awarded upon successful completion of all project phases and assigned tasks.
• Progress Monitoring: To ensure steady progress, you are required to submit a project report to your guide every fortnight for review and feedback.
• Guide and Community Support: You will have direct access to your guide and a dedicated group of past participants, who are available to address your queries and provide timely support.

---

Must Read

The Research Project Training Program by BDG LifeSciences is not just a course but an investment in your future. The fee you pay guarantees unparalleled value, providing you with cutting-edge skills, real-world experience, and the opportunity to contribute to internationally published research. This program is designed to elevate your academic and professional profile, equipping you with expertise in bioinformatics and drug discovery that is highly sought after in today’s competitive job market.

By participating, you gain the chance to learn from seasoned experts, work on innovative projects, and create a strong foundation for careers in bioinformatics, pharmaceutical research, or higher education. The program’s comprehensive structure ensures you receive everything you need to succeed—training, practical application, resources, certifications, and networking opportunities.

Whether you aim to pursue advanced studies, secure a high-impact job, or become a leader in your field, this program opens doors to new possibilities and heights of success. With BDG LifeSciences, you are not just learning—you are building a future where your contributions to science and technology can make a real difference.

---

How To Register

To secure your spot:

• Click on Register Now button and proceed.
• For queries, contact us at research@bdglifesciences.com

---

Resource Person/Trainer

Excellent and highly experience research team lead by Sharvari Kulkarni, CTO, BDG Lifesciences.

---

FEE

Registration Fee
Registration deadline 10 March 2026 or when the 5 seats are filled
Other Countries - Living/Studying/Working outside India	$949 (US)
Participants in India	₹ 86599

---

Previous Events & Testimonials

Gain insight into our past workshops:

• Video Feedback: Visit our YouTube channel for testimonials.
• Upcoming Programs: Explore other upcoming events here.

---

To get regular updates on Upcoming Job opportunities, Research Projects, Courses, Training and Workshops, kindly join our WhatsApp Channel /  Telegram

TEAM FOR CURRENT/ONGOING RESEARCH PROJECTS

92. Mapping Druggable RNA Landscapes: An End-to-End Pipeline from Transcriptomics to Therapeutic Targeting

1. Yana Joshi, Henry M. Jackson High School, WA, USA. 
2. Sharvari Kulkarni, Chief Technical Officer, BDG Lifesciences, India.
3. Ayanjeet Chowdhury, Technical Officer, BDG Lifesciences, India.

91. ImmunoSpatial Blueprint: Mapping Tumor-Immune Interactions in Triple-Negative Breast Cancer Using Spatial Transcriptomics

1. Dr Malu Sreekumar, Jawaharlal Institute of Post-graduate Medical Education and Research (JIPMER), Puducherry, India. 
2. Tanmay Bandbe, Guru Nanak Khalsa College of Arts, Science & Commerce, Mumbai, India.

90. Single-cell RNA-seq Analysis of Chemotherapy-Induced Transcriptomic Changes in Pancreatic Ductal Adenocarcinoma (PDAC)

1. Dr Ilham Mahgoub, Qatar University, Qatar.
2. Ritam Baruah, Ajanta Pharma Limited, Assam, Indi.
3. Aakash Deva Thirukonda Prakash, KTH Royal Institute of Technology, India.

88. Computational Insights into Selective ERβ Agonists for Benign Prostatic Hyperplasia (BPH) Treatment | A Virtual Screening, Molecular Docking & Simulations Study.

1. Shivani Tuli, University of Pittsburg, Pittsburgh, USA.
2. Rakshitha Prakash, Vellore Institute of Technology (VIT), India.
3. Chandrima Das Sinha, Techno India University, India.
4. Swapnaja Gulawani, Agharkar Research Institute, India.
5. Trần Thị Thư, Hồ Chí Minh, Vietnam.

87. Decoding Pan-Cancer Pathogenesis: A Multi-Layered Analysis of Prognostic mRNAs, miRNAs, lncRNAs via Co-Expression Networks and PPINs

1. Ritam Baruah, Ajanta Pharma Limited, Assam, India.
2. Tanmay Bandbe, Guru Nanak Khalsa College of Arts, Science & Commerce, Mumbai, India

86. Unveiling Autoimmune Genes and Regulatory Elements in Head and Neck Squamous Cell Carcinoma through Advanced Machine Learning and Network-Based Analysis

1. Mathews Kennedy, Trivandrum, Kerala, India.
2. Angela Susan Anil, School of Biotechnology, Amrita Vishwa Vidyapeetham, Kerala. 
3. Elham O Mahgoub, Alneelain University, Sudan.

85. Molecular Modeling study of derivatives of Leaf Extracts of medicinal plant Solanum torvum and Serine/Threonine Kinase from Mycobacterium Tuberculosis

1. Tenzin Kalsang, Manipal Academy of Higher Education, India.
2. Elham O Mahgoub, Alneelain University, Sudan.
3. Laxmi C M, Teesside University, Middlesbrough, UK.
4. Ilham Said Salman, Beirut Arab University, Lebanon.

84. Targeting Tumor Progression: Identifying Differentially Expressed Genes and Pathways in Pancreatic Ductal Adenocarcinoma using RNAseq

1. Kasturi Mukherjee, Kyvor Genomics Pvt. Ltd , Chennai, India.

83. Next Generation Sequencing | Unraveling the Cancer Code: Gene Expression Profiling with RNAseq

1. Ilham Omer Mahgoub, Alneelain University, Sudan
2. Arnav Kolluru,Liberty High School, Renton, WA, United States.

82. NGS Data Analysis | Prediction of Multiple Myeloma Using RNASeq Data

1. Dolly Jagwani, Indian Institute of Science Education and Research, Pune (IISER-P), Maharashtra, India
2. Mathews Kennedy, Cancer Biology and Therapeutics, Middlesex University, London, UK.

81. NGS Data Analysis of Cancer Tissues | A Cancer Biology Study

1. Pooja Prakash Mankar, - Shri Shivaji College of Arts, Commerce and Science, Akola, India. 
2. Amit Kumar, ICMR, New Delhi, India.
3. Ilham Omer Mahgoub, Alneelain University, Sudan.

79. Molecular Modeling study of Cyclophilin A and derivatives of Ganoderiol F (26,27-Dihydroxylanosta-7,9(11),24-trien-3-one): Design of novel inhibitors for CyclophilinA

1. Ilham Omer Mahgoub, Alneelain University, Sudan.
2. Sharda Sambhakar, Department of Pharmacy, Banasthali Vidyapith, Rajasthan, India.

78. Molecular Modeling study of derivates of Ethyl 2-[(4-chlorophenyl)carbamoylamino]-5-methyl-4-phenylthiophene-3-carboxylate and α-D-glucose-1-phosphate thymidylyltransferase (Mycobacterium-RmlA) | Discovery of new drugs for multidrug-resistant (MDR)Mtb

1. Jyotishikha, Department of Biotechnology, Amity University, India.
2. Harmanpreet Kaur, Red River College, Winnipeg, Manitoba, Canada.
3. Roma Sharma, Sorting Hat Technologies, India.
4. Yamini Saraswathi Chapala, Bhavans Vivekananda College, Hyderabad, India.

76. Molecular Modelling study of p53-MDM2 and derivatives of Ganoderiol F | Discovery of new Anti-CANCER Drugs by Molecular Docking & MD Simulations Approach

1. Rytis Boreika, Abbaltis, Sittingbourne, United Kingdom.
2. Divya M B, Department of Biochemistry, St Aloysius College, Mangalore, India.
3. Sujoy Chakraborty, Department of Biotechnology, Amity University, India.
4. Roshni Thapa, Special Centre for Molecular Medicine, Jawaharlal Nehru University, New Delhi, India.

75. NGS Data Analysis on Alzheimer's

1. Raajesh Iyer B, Prophecy Technologies, San Diego, CA, USA.
2. Shourya Majumder, Department of Biotechnology, IIT Kharagpur, India.

74. NGS Data Analysis on Cancer Biology | Analyzing cancer tissues

1. Vikram Krishna B, Sri Sankara Arts and Science College (Autonomous), Kanchipuram, Tamilnadu, India.
2. Dexter Achu Mosoh, SAGE University Bhopal Campus, India.
3. Dr.Dheepa Manoharan, Infectious Diseases, Dubai, UAE

73. Inhibitory study of Focal Adhesion Kinase (FAK): A Virtual screening, Molecular Docking & ADMET study for  combating cancer

1. Rutupurna Satapathy, KIIT School of Biotechnology, Orissa, India.
2. Dexter Achu Mosoh, SAGE University Bhopal Campus, India.

72. Virtual Screening and Molecular Docking study of derivatives of chromen-2-one as selective Estrogen Receptor beta Agonists (SERBAs): Molecular Modeling study of Benign Prostatic Hyperplasia

1. Keerthi Renganathan, School of Biotechnology and Bioinformatics, D.Y. Patil University, India
2. Nikita Mundhara, Department of Biotechnology, Indian Institute of Technology Bombay, Mumbai, India.
3. Tanveen Kaur Soni, JIS University, Agarpara, Kolkata, India.
4. Sakshi Pandey, Banaras Hindu University, India.

71. Molecular Modeling Study of extracts of medicinal plants as potential anti-tubercular agents

1. Titiksha Sharma, Delhi Technological University, Delhi, India.
2. Jhancy Raj, Biogenix Research Centre, Thiruvananthapuram, Kerala, India.
3. Awadhesh Kumar Verma, Jawaharlal Nehru University, New Delhi, India.
4. Shaniya Ali, Mar Athanasios College for Advance Studies Thiruvalla, Thiruvalla, Kerala, India.

70. Virtual screening & Molecular Docking of DOT1L & derivatives of Pinometostat | Molecular Modeling study of Therapeutic Target in Mixed-lineage Leukemia (MLL)

1. Lakshmi Prasannah, Department of Pharmaceutical Sciences, Bengaluru, India.
2. Komal Kumari Gohil, K.J. Somaiya College of Science & Commerce, Mumbai,India.
3. Yannick Luther Agbana, Pan African University Life and Earth Sciences Institute, University of Ibadan, Nigeria.
4. Palak Shrivastava, Department of Biotechnology, Dr. Harisingh Gour University, Sagar, India.

69. Targeting the Wnt/β-catenin signaling pathway in cancer by molecular modeling study of Ganoderiol F and Beta- Catenin

1. Mithra M S, Rajiv Gandhi Centre for Biotechnology, India.
2. Nikhil K Gigi, The Institute of Science, Dr. Homi Bhabha State University, Mumbai.
3. Madhumita Ghosh, Ballygunge Science College, University of Calcutta, Kolkata, West Bengal, India
4. Raktim Chowdhury, University of Mumbai, India.
5. Zehratul Quresh, Metropolis Healthcare, Hyderabad, India.

68. Biomarker discovery based on omics technology

1. Bansari Modi, Department of Botany , Bioinformatics, Climate change and impact management, School of Science, Gujarat University, India.
2. Nishant Joshi, Shiva Nadar University, India.

67. Study of SARS-CoV-2 main protease (Mpro) and derivatives of Norterihanin to investigate potential inhibitors using Virtual Screening & Molecular Docking

1. Satabdi Mohanty, Department of Biotechnology & Genetic Engineering, SRM University, India.
2. Dhriti Gaur, Department of Biotechnology , Bennett University, India.
3. Aditya G Lavekar, PI Industries, Rajasthan, India.

66. Molecular Modelling study of SARS-CoV-2 spike protein of COVID-19 with derivatives of Saikosaponins | Examining the anticoronaviral activity of saikosaponins (A, B2, C and D)

1. Amisha Garg, System Biology and Bioinformatics, Panjab University, Chandigarh, India. 
2. Sweta Mohanty, Department of Biotechnology, KIIT University, India.
3. Rudra Prasad Nayak, Department of Biotechnology, KIIT University, India.
4. Suparna Giri, Department of Biotechnology, KIIT University, India.
5. Aakash Deva T.P, School of Bioengineering, SRMIST, Chennai, India.

65. Molecular Modeling study of Southeast Asian Medicinal Plant Aglaia erythrosperma  and α-D-glucose-1-phosphate thymidylyltransferase (Mycobacterium-RmlA) | Discovery of new drugs for multidrug-resistant (MDR) Mtb

1. Arka Sanyal, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India.
2. Ankita Mohanty, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India
3. Saswat Dash, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India
4. Aditi Rubal, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India
5. Anusakha Panigrahi, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India
6. Adrija Dihingia, Department of Biotechnology, KIIT University, Bhubaneshwar, Odisha, India

64.Molecular Modeling study of Cyclophilin A and derivatives of 1,8-Diamino-2,4,5,7-tetrachloroanthraquinone: Design of novel inhibitors for Cyclophilin A 

1. Safiya Aafreen, Biomedical Engineering, Johns Hopkins University , Baltimore, USA.
2. Jyothi Giridhar, Narayana Pharmacy College, JNTU Anantapur, India.
3. Sanica Nadkarni, MGM Institute of Health Sciences, India.
4. Ankita Saha, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee(IITR), Roorkee, Uttarakhand, India.
5. Nirav Parmar, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee(IITR), Roorkee, Uttarakhand, India.
6. Manjari Gaur, Department of Biosciences and Bioengineering, Indian Institute of Technology Roorkee(IITR), Roorkee, Uttarakhand, India.

63. Molecular Modelling study of Catalytic domain of protein kinase PknB from Mycobacterium tuberculosis | Discovery of new Anti-Tubercular Drugs

1. P Ansuman Abhisek, MKCGMCH, Odisha, India.
2. Chitra Roy, Ballygunge Science College, University of Calcutta, Kolkata, India.
3. Ramya Vishwanathan, Biotechnology Engineering, SRM Institute Of Science And Technology, India.
4. Niyati Bisht, Department of Immunology and Virology, Amity University, Noida, India.
5. Mudita Appasaheb Kadam, Maulana Abul Kalam Azad University of Technology, Kolkata, West Bengal, India. 

62. Molecular Modelling study of p53-MDM2 | Discovery of new Anti-CANCER Drugs by Molecular Docking & MD Simulations Approach

1. Ngoc Pham, The Applied Chemistry Department of the International University, Ho Chi Minh, Vietnam.
2. Remya Prajeshgopal, Virology Department, Emirates Modern Poultry Co(Al Rawdah), Dubai, UAE.
3. Shibam Dey, B.Tech+ M. Tech Biotechnology Dual Degree, KIIT University Bhubaneshwar,Odhisa, India
4. Shalini Susmita, B.Tech+ M. Tech Biotechnology Dual Degree, KIIT University Bhubaneshwar,Odhisa, India.
5. Anurag Chatterjee, B.Tech+ M. Tech Biotechnology Dual Degree, KIIT University Bhubaneshwar,Odhisa, India.

61. Molecular modeling of sphingosine 1-phosphate receptor 1(S1P1) as target for multiple sclerosis | A Virtual screening, Molecular docking & ADMET study

1. Veera Raghava Choudary Palacharla, Scientist, Drug Discovery, M.Pharmacy, Annamalai University, India.
2. Dr Arul Amuthan, Division of Siddha, Center for Integrative Medicine and Research (CIMR), Manipal University, India.
3. Sandip Jaiswal, Operations manager (Cloud Platform), CSC, India.
4. Manika Gupta, Master of Science in Genomics, Amity Institute of Virology and Immunology, Amity University, India.
5. Dhanush R A, B. Tech - Genetic engineering, SRM Institute of Science and Technology, India.
6. Poonam Dhiman, BS-MS Integrated Course, Indian Institute of Science Education and Research, Mohali, India.
7. Preethi Varriar, Bachelor of Technology (B. Tech), Biotechnology, Delhi Technological University, India
8. Mohammad Khan, Masters of Science in Bioinformatics, G.N Khalsa College, Matunga, Mumbai, India
9. Shagufta Khan, Masters of Science in Bioinformatics, G.N Khalsa College, Matunga, Mumbai, India.

60. Inhibitory study of α-D-glucose-1-phosphate thymidylyltransferase (Mycobacterium-RmlA) | Discovery of new drugs for multidrug-resistant (MDR) Mtb

1. Prof. Dr. Ali Abdulhafidh Ibrahim Al-Shaikhli, Department of Mathematical and applied computer, College of Science, Al-Nahrain University, Jadriyah, Baghdad, Iraq.
2. Dr. Prince Prashant Sharma,Gurukula Kangri Vishwavidyalaya, Department of Pharmaceutical Sciences, Haridwar, India.
3. Gauri Kiran Vanjari, Bachelor of Dental Surgery, SASS Yogita Dental College and Hospital, Maharashtra University of health Sciences, Nasik, India.
4. Shivam Bhan, B.Tech Biotechnology, Amity University, Noida, UP, India.

59. Molecular modeling study of derivatives of dutasteride and Human Steroid 5β-Reductase (AKR1D1) | Discovery of new drugs for prostate cancer

1. Chhavi Rai, BDG LifeSciences, India.
2. Vinay Kumar, BDG LifeSciences, India
3. Dipjyoti Dey, Master of Science Applied Microbiology, Vellore Institute of Technology (VIT) University, Vellore, India.
4. Mehuli Mishra, B.Sc, Department of Biotechnology, Jyoti Nivas College, Bengaluru, India
5. Vidushi Aggarwal, B.Sc, Department of Biotechnology, Jyoti Nivas College, Bengaluru, India.
6. Disha Mitra, Biophysics, Molecular Biology and Bioinformatics, Rajabazar Science College, Calcutta University, India.
7. Suparna Maji, B.Tech M.Tech Dual Degree in Biotechnology, KIIT University, Bhubaneswar, Odisha, India
8. Soumyadipta Das, B.Tech M.Tech Dual Degree in Biotechnology, KIIT University, Bhubaneswar, Odisha, India
9. Suman Nayek, B.Tech M.Tech Dual Degree in Biotechnology, KIIT University, Bhubaneswar, Odisha, India.
10. Subarna Chakraborty, B. Tech Genetic Engineering, SRM Institute of Science and Technology, India.

57. Molecular modeling study of α-glucosidase Inhibitors (AGIs) | Discovery of new anti-diabetic drugs by controlling postprandial hyperglycemia

1. Dr Minakshi Garg PhD, Assistant Professor in Biotechnology, University Institute of Engineering and Technology, Panjab University Chandigarh, India
2. M. Raghanivedha, Master of science in Biotechnology, Seattle, Washington, United States of America.
3. Shreya Mondal, B. Tech (Biotechnology), Amity University, Noida, India.
4. H. Vijayasri, B.Sc. (Hons) Biomedical Sciences at Sri Ramachandra Institute of Higher Education and Research (DU) Porur, Chennai.
5. Nikita Yadav, BS-MS Integrated Course, Indian Institute of Science Education and Research, Mohali, India
6. Sucharita Ghosh, B.Tech M.Tech Dual Degree in Biotechnology, KIIT University, Bhubaneswar, Odisha, India.

56. Discovery of new ligands for PPAR Gamma responsible for Diabetes Type 2: A Virtual Screening, Docking & ADMET Study.

1. Bharti Mittal, PhD, Senior Scientist, Operations, MedGenome Labs Pvt Ltd, Bangalore, India.
2. Vivek Srivastava, Ph.D., Assistant Professor(Biochemistry), School of Basic Sciences and Research, Sharda University, Greater Noida, UP
3. Maitili Varma, Advanced Proficiency course in Genetic engineering, Genohelix Biolabs, Jain Group of Institutions, India.
4. Priyadarshini Sharma, B. Tech, Amity Institute of Biotechnology, Amity University, Noida, India.
5. Harshita Agarwal, B. Sc, Amity Institute of Biotechnology, Amity University, Noida , India.
6. Gupta Radha Devi Shivprakash, Masters of Science in Bioinformatics, G.N Khalsa College, Matunga, Mumbai, India
7. Raisa Dabhilkar, Masters of Science in Bioinformatics, G.N Khalsa College, Matunga, Mumbai, India.

53. Molecular Modelling study of phytoconstituents from medicinal plants of India | Discovery of natural anti-tubercular agents

1. Taiba Hamed Youssef Gamal El Din, Master in Biotechnology & Life Science, Bani Sueif University, Bani Sueif, Egypt.
2. Syeda Birjees Misbah, M.Sc., Biochemistry, REVA University, Bangalore, India.
3. Aindrila Pal, B. Tech, Amity Institute of Biotechnology, Amity University, Noida, India.
4. Preeti, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
5. Ngoc Pham, The Applied Chemistry Department of the International University, Ho Chi Minh, Vietnam.
6. Moumita Ganguly, Research Associate, IIT Mandi, India.
7. Deeksha Gairola, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
8. Ketaki Ghatole, B.E. Biotechnology, MS Ramaiah Institute of Technology, Bengaluru, India.

49. Molecular Modeling study of Zika Virus | Virtual Screening, Protein Modeling, Docking, ADMET and MD Simulations Study

1. Dr. Alam El-Din, Hanaa Mahmoud, Virology and Immnunology Unit, Cancer Biology Department, National Cancer Institute, Cairo University, Cairo, Egypt.
2. Manjisa Choudhury, VIT University, Vellore, India.
3. Nada Gamal Ibrahim El-Dawy, Faculty of Biotechnology, October University for Modern Sciences and Arts, Egypt (MSA University).

39. Study of derivatives of Chalcones as new Tyrosinase inhibitors: A Molecular Docking, ADME & Tox Study

1. Adwaita Das, Department of Botany, The University of Burdwan, Burdwan, West Bengal, India
2. Shreya John MSc Bioinformatics, St. Aloysius Institute of Management and Technology, Mangalore University.
3. Lalit R. Samant, Project Assistant, Haffkine Institute for Training Research and Testing, India.
4. K.C. Haritah Yadav, M. Sc (Medical Pharmacology) from Kamineni Institute of Medical Sciences, Narkrtpally, Nalgonda, Andhra Pradesh.
5. Dr. N. Hari, School of Chemical & Biotechnology, SASTRA University, Thanjavur, Tamil Nadu.
6. Dr(Mrs) Jhaumeer Laulloo Sabina, University of Mauritius, Reduit, Mauritius.

34. Study of extracts of Veratrum Dahuricum as potential Anti-tumor molecules: Molecular Docking & Modeling study with Farnesyl Pyrophosphate Synthase (FFPS)

1. Gomathi Rajendran, ITC Zenith (M) Sdn. Bhd. (Conformity Assessment Body), Malaysia.
2. Seetha Harilal, Department of Pharmacology, Nehru College of Pharmacy, Kerala University of Health Sciences, Thrissur, Kerala, India.
3. Akshya Kumar Mailapali, I. M.Sc Bioinformatics , B.J.B. Autonomous College, Utkal University, Bhubaneshwar, India.
4. Tanya Munjal, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
5. Sambit Kumar Roy, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
6. Lucky Gupta, M.Sc Biotech, Amity Institute of Biotechnology, Amity University, India.
7. Gaurav Dutt, School of Basic and Applied Science, Dayananda Sagar University, Bangalore, India.